




Curriculum Vitae

Personal Information	
Title	Professor
Name	Toshifumi Hibi
Degree	MD., Ph.D.
Country	Japan
Affiliation	Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
	
Educational Background	
1968-1973	School of Medicine, Keio University, Tokyo, Japan -Medicine
1973-1977	Postgraduate School, Keio University, Tokyo, Japan - Internal Medicine
Professional Experience	
1975-1977	Clinical Fellow in Gastroenterology, Keio University Hospital, Tokyo, Japan
1977-1980	Instructor in Gastroenterology, National Ookura Hospital, Tokyo, Japan
1980-1982	Instructor in Gastroenterology, Keio University Hospital, Tokyo, Japan
1982-1985	Postdoctoral Fellow in Immunology, University of Toronto, Toronto, Canada
1985-1988	Chief in Division of Gastroenterology, Kitasato Institute Hospital, Tokyo, Japan
1989-1990	Instructor in Gastroenterology, Keio University Hospital, Tokyo, Japan
1990-1995	Head, Keio Cancer Center, Tokyo, Japan Associate Professor, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
1996-2002	Director, Keio Cancer Center, Tokyo, Japan
2002-2004	Director, Center for Comprehensive and Advanced Medicine, Keio University Hospital, Tokyo, Japan
1995-2004	Professor, Department of Medicine, Keio University School
2004-2013	Professor and Chairman, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
2013-2022	Project Professor and Director Center for Advanced Therapy for Inflammatory Bowel Disease Kitasato Institute Hospital Graduate School of Medical Sciences The Kitasato Institute Kitasato University Honorary professor Keio University School of Medicine
2022- present	Honorary professor Keio University School of Medicine Special Advisor Center for Advanced IBD Research and Treatment Kitasato Institute Hospital Kitasato University
Professional Organizations	
American Gastroenterological Association American College of Gastroenterology European Crohn's and Colitis Organisation Japanese Society of Gastroenterology	



Japanese Society of Internal Medicine
Japanese Society of Lymphology
Japan Society for Clinical Immunology
Japan Society of Colon Examination
Japan Society of Coloproctology
Japan Gastroenterological Endoscope Society
Society for Mucosal Immunology
Japanese Society for Inflammatory Bowel Disease
Asian Organization for Crohn's & Colitis

Main Scientific Publications

1. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients with Inflammatory Bowel Diseases: Systematic Review and Meta-analysis. Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Kinoshita K, Alocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Clin Gastroenterol Hepatol May;19(5):908-921 2021
2. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T, on behalf of the HAYABUSA Study Group. Lancet Gastroenterol Hepatol Jun;6(6):429-437.2021
3. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial Feagan BG, Danese S, Loftus Jr EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempinski R, Filip R, Hospodarsky I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L The Lancet Jun 19;397(10292):2372-2384 2021
4. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T Alimentary Pharmacology & Therapeutics Feb 25 doi:10.1111/apt.16817. Online ahead of print. 2022
5. AJM300 (carotegrast methyl), an oral antagonist of $\alpha 4$ -integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Matsuoka, K; Watanabe, M; Ohmori, T; Nakajima, K; Ishida, T; Ishiguro, Y; Kanke, K; Kobayashi, K; Hirai, F; Watanabe, K; Mizusawa, H; Kishida, S; Miura, Y; Ohta, A; Kajioka T, Hibi T, Lancet Gastroenterol Hepatol Jul;7(7):648-657.
6. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open Matsuoka K, Hisamatsu T, Kim HJ, Ye BD, Arai S, Hoshi M, Yuasa H, Tabira J, Toyozumi S, Shi N, Woo Js, Hibi T Journal of Gastroenterology Online ahead of print.